Ipamorelin / GHRP-2 Blend
Two agonists of the same receptor — and the vendor doesn't disclose the split.
For research purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm these products will be used for legitimate research purposes.
About Ipamorelin / GHRP-2 Blend
A 20mg vial combining Ipamorelin and GHRP-2. Two things make this the hardest blend here to recommend. First, both components act on the same receptor. Ipamorelin and GHRP-2 are both GHS-R1a agonists, so unlike every other blend in this catalog there is no second mechanism being added — this is one pathway addressed twice. What the GHRP-2 does contribute over Ipamorelin alone is appetite stimulation plus a cortisol and prolactin rise, which is precisely the side-effect profile Ipamorelin exists to avoid. There is no GHRH component to complement either of them. Second, the vendor does not state how the 20mg is divided between the two peptides. Without that, per-component dosing cannot be calculated at all — you can compute a total draw volume but not how much of each compound is in it. For a compound class where the difference between the two components is the entire point, that is a meaningful transparency gap.
Key Benefits
- Single vial rather than two reconstitutions
- Both components have individual human data
Set a goal (top of the page) to see how Ipamorelin / GHRP-2 Blend scores against it, and what the better-evidenced alternatives are.
Category Ratings
How to Take
Common Side Effects
- Increased appetite from the GHRP-2 component
- Transient cortisol and prolactin elevation — the effects Ipamorelin alone avoids
- Water retention
- Tingling or numbness in hands
- Undisclosed component ratio makes exposure to each peptide unknown
Legal & Regulatory Status
Research use only; not FDA-approved. Both components have individual human data but act on the same receptor; no study exists on the combination. Both are WADA-prohibited.
Safety and regulatory details for FDA-approved compounds are drawn from the official product label via openFDA; clinical development status reflects ClinicalTrials.gov. This information is provided for research reference, is not endorsed by the FDA, and may not be complete or current.
Research & Sources
- Pralmorelin (GHRP-2) drug profile and development status (PMID 15230633)
- Phase 2 trial: ipamorelin for postoperative ileus (PMID 25331030)
- GHRP-2, like ghrelin, increases food intake in healthy men (PMC2824650)
Sources are selected for reliability (peer-reviewed literature, openFDA, ClinicalTrials.gov) but this is a research summary, not medical advice, and may not be exhaustive.
Prices at quality-checked sources · as of August 2026 (8 days ago)
- 20mg total (split not disclosed) $151.47
Observed on each vendor’s public listing — see how these sources are vetted. Peptide Concierge doesn’t sell peptides and isn’t affiliated with any vendor; confirm current pricing at the source.
Builds a working set shared across the stack builder, calculator, scheduler and compare.